Search
for
Did you mean Estrogen Receptor-Positive Breast Cancer?
Sort by
Research 30 of 1000+
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
- Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Environmental factors influencing hormone receptor positive breast cancer incidence: integrating chemical signatures from dust wipes with self-reported sources of exposure
- The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
- Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells
- Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
- Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
- Aldosterone- and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer
- Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
- Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis
- Ductal breast cancer in a male patient
- A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
- Aromatase inhibitors induce ‘male pattern hair loss’ in women?
- A case of aromatase inhibitor‐induced alopecia successfully treated with low‐dose oral minoxidil
- Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Evaluation of the Hemogram of Breast Cancer Patients Treated by Therapeutic Protocol Based on Immunohistochemical Analysis: A Retrospective Study
- Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings
- Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
- Hormone Blocking Anticancer Drugs
- Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
- Thiohydrazides in the Synthesis of Functionalized Extranuclear Heterosteroids
- Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
- Female pattern hair loss possibly caused by tamoxifen: Androgen receptor expression in the outer root sheath in the affected area
- Cancer risk in polycystic ovary syndrome patients: Common treatments and future perspectives
- Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
- Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.